Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Operating Leases: 2022-2023

Historic Operating Leases for Candel Therapeutics (CADL) over the last 2 years, with Sep 2023 value amounting to $1.1 million.

  • Candel Therapeutics' Operating Leases fell 31.16% to $1.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.1 million, marking a year-over-year decrease of 31.16%. This contributed to the annual value of $1.5 million for FY2022, which is N/A change from last year.
  • According to the latest figures from Q3 2023, Candel Therapeutics' Operating Leases is $1.1 million, which was down 10.51% from $1.2 million recorded in Q2 2023.
  • Candel Therapeutics' Operating Leases' 5-year high stood at $1.8 million during Q1 2022, with a 5-year trough of $1.1 million in Q3 2023.
  • Moreover, its 2-year median value for Operating Leases was $1.5 million (2022), whereas its average is $1.5 million.
  • Data for Candel Therapeutics' Operating Leases shows a maximum YoY tumbled of 31.16% (in 2023) over the last 5 years.
  • Over the past 2 years, Candel Therapeutics' Operating Leases (Quarterly) stood at $1.5 million in 2022, then tumbled by 31.16% to $1.1 million in 2023.
  • Its last three reported values are $1.1 million in Q3 2023, $1.2 million for Q2 2023, and $1.4 million during Q1 2023.